Original HTML
Leading Biotech Selects Veeva Vault CRM Globally
Agentic CRM foundation to help accelerate the delivery of innovative medicines to patients worldwide
PLEASANTON, Calif., Sept. 15, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.
"Moving to Vault CRM will help accelerate our efforts to bring new therapies to patients globally with greater speed and agility," said Scott Skellenger, senior vice president and chief information officer at Amgen. "Veeva's deep understanding of life sciences, its continued focus on innovation, and our long-standing collaboration will help support Amgen in achieving these important goals."
"Vault CRM will provide the agentic commercial foundation to help Amgen deliver innovative medicines for some of the world's toughest diseases to millions of patients," said Matt Farrell, president, commercial strategy at Veeva. "We look forward to supporting Amgen as it launches important new therapies worldwide."
Vault CRM is part of the Vault CRM Suite, the technology foundation for agentic commercial, transforming how the industry engages with healthcare professionals (HCPs) to accelerate launch performance and improve patient outcomes. It includes the Agentic Call Report to generate Commercial Evidence and uncover previously hidden treatment barriers.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
SOURCE Veeva Systems
Share this article
Original Summary
<p>Agentic CRM foundation to help accelerate the delivery of innovative medicines to patients worldwide PLEASANTON, Calif., Sept. 15, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Amgen to Deploy Veeva Vault CRM Globally for Drug Launches", "body_html": "<p><strong>Pleasanton, Calif. -- [CURRENT_DATE] --</strong> Amgen plans to deploy Veeva Vault CRM globally, extending a collaboration between the two companies that spans more than a decade, Veeva Systems (NYSE: VEEV) announced.</p><h5>Amgen shifts to agentic commercial infrastructure for global drug launches</h5><p>The deployment will make Vault CRM the commercial technology foundation across Amgen's worldwide operations. Scott Skellenger, senior vice president and chief information officer at Amgen, said the move to Vault CRM is intended to accelerate the delivery of new therapies to patients globally with greater speed and agility.</p><h5>Vault CRM Suite adds Agentic Call Report to surface treatment barriers</h5><p>Vault CRM is part of Veeva's broader Vault CRM Suite, positioned as the technology base for agentic commercial operations across the life sciences industry. The suite includes the Agentic Call Report, a tool designed to generate what Veeva terms Commercial Evidence and identify previously hidden treatment barriers in how pharmaceutical companies engage healthcare professionals.</p><p>Matt Farrell, president of commercial strategy at Veeva, said Vault CRM will support Amgen as it launches new therapies worldwide, providing what he described as an agentic commercial foundation for delivering medicines for serious diseases to millions of patients.</p><h5>Veeva counts more than 1,500 life sciences customers globally</h5><p>Veeva serves more than 1,500 customers ranging from large pharmaceutical companies to emerging biotechs, offering applications, agents, data, and consulting services under its industry cloud model for life sciences.</p>", "meta_description": "Amgen will deploy Veeva Vault CRM globally, adopting an agentic commercial platform to speed drug launches and uncover treatment barriers via new Call Report tool.", "seo_keywords": "Veeva Systems, Amgen, Vault CRM, agentic commercial, life sciences CRM, pharmaceutical technology, drug launch, Commercial Evidence", "companies": ["Veeva Systems", "Amgen"], "industries": ["Biopharmaceuticals"], "markets_regions": ["Global"], "news_type": ["product_launch", "general_news"], "products": ["Veeva Vault CRM"], "themes": ["digital_transformation", "supply_chain"], "events": [], "cta_text": "Details on the Amgen-Veeva collaboration and Vault CRM Suite capabilities", "learn_more": "https://veeva.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
b5fc8805957e283313cd9f5194564131
